1. HIV portends a poor prognosis in myelodysplastic syndromes
- Author
-
Kith Pradhan, Anjali Sharma, Yanhua Wang, Ashwin Sridharan, Santiago Thibaud, Amer Assal, Amit Verma, Barry S. Zingman, Aditi Shastri, Ulrich Steidl, Rahul Polineni, Ira Braunschweig, Britta Will, Mark Chaitowitz, Justin D. Kaner, Murali Janakiram, Sakshi Jasra, Louis M. Weiss, Ioannis Mantzaris, and Harold Elias
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Poor prognosis ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Aged ,Retrospective Studies ,business.industry ,Myelodysplastic syndromes ,Clinical course ,HIV ,virus diseases ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Mutation ,Female ,business ,Follow-Up Studies ,030215 immunology - Abstract
Even though HIV is associated with worse prognosis in many malignancies, the clinical course of myelodysplastic syndrome (MDS) in HIV + patients has not been well studied. Determining the clinical presentation and outcomes of MDS in these patients would be important for future diagnostic strategies, as anemia and other cytopenias are commonly seen in HIV + patients. Unique data mining software was used to identify cases of MDS or AML in adult patients who were also HIV + at Albert Einstein/Montefiore Medical Center between 1 January 2003 and 1 January 2017. Using Chi-Square and Fisher's exact test, characteristics of the HIV + MDS patients were compared to 135 HIV - MDS patients from the same institution diagnosed between 1997 and 2011. Fourteen biopsy proven MDS patients were identified with concomitant HIV. HIV + MDS patients presented at a younger age (59 vs. 71 yrs
- Published
- 2019